Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.

Blood · 2025 · PMC12824667 · PMID 40009500

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Similar to OS, other efficacy end points showed a trend for worse outcomes in the Magro/Aza groups vs the respective controls, and ORRs were lower with Magro/Aza vs either control.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.